Google
Trusted Resources: News & Events
Latest announcements and gatherings
ASH launches sickle cell disease clinical trials network to accelerate therapy development
ASH launched a clinical trials network designed to accelerate development of novel therapies for patients with sickle cell disease.
The network will match clinical trial sponsors with research sites, facilitate patient recruitment and provide consulting services. A core component will be a centralized data repository developed and maintained by ASH.
“We are on the brink of a new era in sickle cell disease research and treatment. Interest in this disease is expanding, with more than 40 treatments and more than a dozen devices in the research and development pipeline,” ASH President Alexis A. Thompson, MD, MPH, professor of pediatrics in the division of hematology, oncology and stem cell transplantation at Northwestern Medicine and associate director of equity and minority health at Ann and Robert H. Lurie Children’s Hospital of Chicago, said in a press release.
+myBinderRelated Content
-
Crizanlizumab 5.0 mg/kg increased the time to first on-treatment sickle cell pain crisis (SCPC) and the likelihood o...Background: In the 52-week SUSTAIN stud...
-
Gene therapies could transform the treatment of sickle cell diseaseManny Johnson keeps catching h...
-
Nutritional Status, Nutrient Intake, and Food Diversity Among Children With Sickle Cell AnemiaChildren with sickle cell anemia (SCA) o...
-
Phase 1 trial to test under-the-skin injection of sevuparin in sickle cell patientsModus Therapeutics is going to launch ...
-
Investigational Therapy Altemia Achieves Main Endpoints in Pediatric Sickle Cell TrialSancilio Pharmaceuticals says its invest...
-
L-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
BCL11A-based gene therapy for sickle cell disease passes key preclinical testA precision-engineered gene therapy viru...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.